{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:53:37Z","timestamp":1767192817071,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:00:00Z","timestamp":1598054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ymgmr.2020.100643","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T12:06:11Z","timestamp":1599653171000},"page":"100643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: Evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials"],"prefix":"10.1016","volume":"25","author":[{"given":"Hitomi","family":"Nishizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masumi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kosho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2020.100643_bb0005","series-title":"Pediatric Bone: Biology & Diseases","first-page":"771","article-title":"Hypophosphatasia","author":"Whyte","year":"2012"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0889-8529(18)30342-6","article-title":"Heritable metabolic and dysplastic bone diseases","volume":"19","author":"Whyte","year":"1990","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0022-3476(82)80061-9","article-title":"Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease","volume":"101","author":"Whyte","year":"1982","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2018.07.006","article-title":"Pyridoxal 5\u2032-phosphate and related metabolites in hypophosphatasia: effects of enzyme replacement therapy","volume":"125","author":"Akiyama","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0040","first-page":"1","article-title":"Improving clinical trial design for Duchenne muscular dystrophy","volume":"153","author":"Merlini","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/mus.26690","article-title":"Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy","volume":"61","author":"Nagy","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0055","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","article-title":"Motor function measure: validation of a short form for young children with neuromuscular diseases","volume":"94","author":"De Lattre","year":"2013","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymgmr.2020.100643_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10131","article-title":"Reliability and validity of the 6-minute walk test in Hypophosphatasia","volume":"3","author":"Phillips","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.ymgmr.2020.100643_bb0070","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.2014.13128","article-title":"Minimal clinically important difference","volume":"312","author":"McGlothlin","year":"2014","journal-title":"JAMA"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:04Z","timestamp":1762001524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426920300896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":14,"alternative-id":["S2214426920300896"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100643","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: Evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100643"}}